acalabrutinib
AssetAlso ACP-196
Inhibits Bruton tyrosine kinase, reducing B-cell receptor signaling and inflammatory immune activation.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Inflammation
- 1
- Indication
- 1,100
- Trials
- 1
- Developer
Indications
1Rheumatoid arthritis
Phase 2, Completed, NCT02387762, clinicaltrials.gov, 12 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials1,100
- Evidence for its targets3
- Competitors12
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.